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Editorial Comment 
Clot-Specific Thrombolytic 
Agents: Is There an Advantage?* 
BERTRAM PITT, MD, FACC 
Ann Arbor, Michigan 
Over the past few years there has been considerable effort to 
develop clot-specific thrombolytic agents. The development 
and initial clinical studies of human recombinant tissue plas-
minogen activator (rt-PA) has aroused great interest and 
expectations for improved thrombolysis and, hence, survival 
after myocardial infarction with a reduced risk of severe 
bleeding. The German Activator Urokinase Study (GAUS) (1) 
reported in this issue of JACC and other recent data raise 
questions as to the advantage of clot-specific thrombolytic 
agents in general and rt-PA in particular. 
The GAUS study compared 3.0 million U of urokinase 
with 70 mg of single chain rt-PA in patients seen within 6 h 
of onset of symptoms of acute myocardial infarction. The 
investigators found a similar patency rate of the infarct-
related artery at 90 min, similar improvement in flow as 
assessed by Thrombolysis in Myocardial Infarction (TIMI) 
grade, a similar improvement in left ventricular function and 
a similar incidence of major bleeding, exclusive of bleeding 
at puncture sites. There did, however, appear to be an 
advantage for rt -PAin regard to patency of the infarct-
related artery in the subset of patients undergoing throm-
bolysis from 3 to 6 h after symptom onset. 
rt·PA versus urokinase or streptokinase. Although it is 
difficult to be certain of the relative efficacy and risks of the 
two agents in view of the relatively low dose ofrt-PA used in 
this study, i.e., 70 mg compared with the current United 
States Food and Drug Administration recommendation of 
100 mg, and the concomitant use of heparin and oral anti· 
coagulants, it seems reasonable to conclude that the risk of 
bleeding is probably not lower with the clot-specific agent 
rt-PA than with the systemic fibrinolytic agent urokinase. In 
fact, it is reasonable to expect that any higher patency rate 
achieved by increasing the dose of rt-PA would be accom-
panied by a concomitant increase in bleeding rates. The 
finding in the present and previous studies that rt -P A appears 
to maintain its thrombolytic potential over a longer time than 
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do urokinase and streptokinase, whose thrombolytic effect 
diminishes over time, suggests an advantage for rt-PA's use. 
Should streptokinase improve survival when administered 
up to 24 h after the onset of symptoms of infarction (as 
recently suggested by the International Study of Infarct 
Survival [ISIS-II] study [2]), one could postulate that rt-PA, 
which appears to be more effective than urokinase and 
streptokinase when given late, would be even more effective 
in improving survival if survival is, as assumed, related to 
initial patency of the infarct-related artery. This assumption 
may not be valid, however, because final patency of the 
infarct-related artery depends not only on the initial opening 
rate but on the incidence of reocclusion, which as suggested 
in the GAUS study (1) may be greater with rt-PA in view of 
its relatively shorter half-life and relative lack of systemic 
fibrinolytic effect. The importance of a systemic fibrinolytic 
effect for maintaining patency of the infarct-related artery is 
also suggested by the recent Thrombolysis and Angioplasty 
in Myocardial Infarction (TAMI-II) study (3) in which a 
combination of rt-PA and urokinase resulted in a significant 
reduction in reocclusion compared with the use of rt-PA 
alone in the TAM I study. That the ability of rt-PA to lyse 
older clots is greater than that of urokinase and streptokinase 
may, on the other hand, be a disadvantage in regard to serious 
bleeding complications. Lysing of small nonocclusive thrombi 
sealing a potential bleeding site in the cerebral circulation, 
with a resultant major bleeding episode if the thrombus was 
present for several hours or days, may be more likely with 
rt-PA than with either urokinase or streptokinase. Factors 
other than final patency rate and bleeding rate, such as the 
incidence of allergic reactions and incidence of severe hypo-
tension, must also be considered and may in some circum-
stances favor rt-PA. 
Clearly the issue as to the relative risk/benefit and cost/ 
benefit ratios of rt -P A compared with either streptokinase or 
urokinase will not be resolved until we have the results of 
direct prospective randomized trials such as Gruppo Italiano 
per 10 Studio della Streptochinasi nell'Infarto (GISSI-II), 
which is comparing streptokinase with rt-PA. Until the 
results of these trials are available, the decision as to which 
thrombolytic agent to use must be a matter of conjecture. 
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